Breast cancer drugs market was valued at approximately $37.0 billion in 2025 and is projected to reach around $91.8 billion by 2035, expanding at a CAGR of 9.6% over the forecast period from 2026 to 2035. This steady expansion is primarily driven by the rising global prevalence of breast cancer, which continues to place a significant burden on healthcare systems worldwide. According to the American Cancer Society, breast cancer remains one of the most diagnosed cancers, leading to a sustained increase in demand for effective and advanced treatment options. The growing patient population is accelerating the adoption of targeted therapies, immunotherapies, and combination regimens, which offer improved efficacy and personalized treatment outcomes.

Bone Morphogenetic Protein (BMP) market is poised for steady growth, with valuations expected to rise from $452.6 million in 2025 to $772.2 million by 2035, reflecting a CAGR of 5.6%. This trajectory is fueled by the global rise in orthopedic disorders and a corresponding increase in surgical interventions. Clinical evidence from PubMed Central confirms that BMPs offer superior bone repair and spinal fusion outcomes compared to traditional grafts, effectively reshaping regenerative medicine. By significantly reducing recovery times and surgical complications, these biologics have become essential in complex healing procedures. Consequently, hospitals maintain their position as the primary end-users, driven by high procedural volumes and the infrastructure to support advanced bone-healing technologies

Bipolar disorder market was valued at $9.7 billion in 2025 and is projected to reach $15.5 billion by 2035, growing at a CAGR of 4.8% from 2026 to 2035. The rising global burden of mental health disorders primarily drives growth. According to the World Health Organization (September 2025), more than 1 billion people worldwide are living with mental health conditions, highlighting a substantial unmet need for treatment and care. This burden includes bipolar disorder, which affects around 37 million people globally, significantly driving demand for effective therapies. The increasing prevalence is pushing healthcare systems to expand mental health services and treatment access. Additionally, improved diagnosis rates and growing awareness are enabling earlier intervention and long-term disease management. Expanding access to pharmacotherapy is further accelerating market growth.

Anal fistula therapeutics market was valued at $1.31 billion in 2025 and is projected to reach $2.39 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). Market growth is driven by the increasing prevalence of gastrointestinal disorders and rising adoption of minimally invasive surgical procedures. According to PubMed Central, advancements in treatment strategies for Crohn’s disease highlighted the growing use of biologics and stem cell-based therapies to manage complications such as anal fistulas. The study emphasized improved patient outcomes through targeted therapies and minimally invasive approaches. These developments are expected to indirectly drive innovation and demand in the anal fistula therapeutics market, particularly in regenerative and biologic treatment segments.

Account-based analytics software market was valued at approximately $5.5 billion in 2025 and is anticipated to reach $16.2 billion by 2035, registering a CAGR of 11.4% over the forecast period. This growth is largely driven by the accelerating pace of digital transformation across industries. In particular, the pharmaceutical sector is increasingly adopting data-driven strategies to target healthcare providers (HCPs) and institutions more effectively. The rising need for precise account targeting, personalized engagement, and measurable ROI is further fueling demand. Additionally, advancements in AI-powered analytics and cloud-based platforms are enhancing decision-making capabilities. As a result, organizations are increasingly investing in account-based analytics solutions to improve marketing efficiency and sales outcomes.

3D food printing market was valued at $330.0 million in 2025 and is projected to reach $1,780.0 million by 2035, expanding at a CAGR of 18.5% over the forecast period. This growth is largely driven by increasing demand for personalized nutrition and the adoption of automation in food production across healthcare and foodservice sectors. Rising health concerns and the need for customized dietary solutions are further accelerating market expansion. According to the World Health Organization (WHO), over 422 million people worldwide are living with diabetes, highlighting the growing need for tailored nutritional intake. 3D food printing enables the development of precision-based, texture-modified, and nutrient-specific foods. Such capabilities make it highly suitable for clinical nutrition and elderly care applications. Additionally, ongoing research and technological advancements continue to strengthen its role in the future of food innovation.

Psoriasis drug market was valued at $27.50 billion in 2025 and is projected to reach $66.90 billion by 2035, growing at a CAGR of 10.37% during the forecast period (2026–2035). The increasing global burden of chronic autoimmune diseases and rising adoption of biologics are significantly driving market growth. According to the World Health Organization, psoriasis affects more than 125 million people globally, representing a substantial patient pool requiring long-term treatment. The disease is associated with systemic complications such as cardiovascular disorders and psoriatic arthritis, further increasing treatment demand. Biologics and targeted therapies are increasingly being adopted due to their superior efficacy in moderate-to-severe cases, while topical therapies continue to dominate mild cases, supporting balanced growth across treatment categories.

Renal cancer drug market was valued at $7.05 billion in 2025 and is projected to reach $13.61 billion by 2035, growing at a CAGR of 6.8% during the forecast period (2026–2035). The rising prevalence of kidney cancer and increasing demand for targeted oncology therapies are significantly driving market growth. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2022, with kidney cancer representing a growing share of urological malignancies. The increasing incidence of renal cell carcinoma, particularly among aging populations, is strengthening demand for advanced drug therapies including immunotherapy and targeted therapy. The market is witnessing a strong shift toward precision medicine and biologic therapies. Regulatory approvals and clinical advancements are accelerating the adoption of immune checkpoint inhibitors and combination therapies. The U.S. Food and Drug Administration continues to approve novel oncology drugs targeting renal cancer, supporting improved treatment outcomes.

Rotary pump market was valued at $8.35 billion in 2025 and is projected to reach $13.40 billion by 2035, growing at a CAGR of 4.84% during the forecast period (2026–2035). The rising global demand for efficient fluid handling systems across industrial applications is a key macro driver supporting market growth. According to International Energy Agency, global oil demand reached approximately 102 million barrels per day in 2023, reflecting strong upstream and downstream activity. Rotary pumps play a critical role in transferring viscous fluids such as crude oil, chemicals, and wastewater with high efficiency and minimal pulsation. Increasing investments in energy, chemical processing, and water infrastructure are strengthening the adoption of advanced rotary pumping solutions across industries. Industrial expansion across oil & gas, chemical & petrochemical, and water & wastewater sectors continues to support steady demand for rotary pumps. According to UN Comtrade Database, global trade in chemical products exceeded $5 trillion in 2023, highlighting the scale of fluid handling requirements across production and distribution processes. 

Scopolamine market was valued at $209.8 million in 2025 and is projected to reach $439.4 million by 2035, growing at a CAGR of 4.3% during the forecast period (2026–2035). The rising prevalence of motion sickness, postoperative nausea and vomiting (PONV), and gastrointestinal disorders is significantly driving demand for scopolamine-based therapeutics across global healthcare systems. Increasing surgical procedures and expanding travel activities are further contributing to the growth of antiemetic drug demand worldwide. According to the World Health Organization, approximately 234 million major surgical procedures are performed annually worldwide, highlighting the growing need for effective PONV management solutions. Scopolamine, particularly in transdermal patch form, plays a critical role in reducing postoperative nausea, improving patient recovery outcomes, and enhancing healthcare efficiency.